
Sign up to save your podcasts
Or


In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option for patients with PD-L1-positive advanced non–small cell lung cancer, and a novel psychosocial digital application that improves fatigue and distress in patients with multiple myeloma.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.6
5656 ratings
In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option for patients with PD-L1-positive advanced non–small cell lung cancer, and a novel psychosocial digital application that improves fatigue and distress in patients with multiple myeloma.
LINK TO FULL TRANSCRIPT

321 Listeners

504 Listeners

39 Listeners

65 Listeners

756 Listeners

121 Listeners

2,262 Listeners

818 Listeners

187 Listeners

46 Listeners

32 Listeners

828 Listeners

59 Listeners

195 Listeners

45 Listeners